BNP Paribas Financial Markets’s Perspective Therapeutics CATX Stock Holding History
Bought
Maintained
Sold
Other funds holding CATX
TCM
CC
APM
AAA
SSC
BNP Paribas Financial Markets's CATX Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its Perspective Therapeutics (CATX) stake by 458% in Q2 2026, buying an estimated $375K and bringing the position to 120,889 shares worth $412K. The position accounts for ﹤0.01% of the portfolio, ranked #3863.
BNP Paribas Financial Markets first reported a position in CATX in Q4 2013 and has held it in 17 quarters since. The position peaked at $835K in Q2 2025. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.
- BNP Paribas Financial Markets held 120,889 shares of Perspective Therapeutics worth $412K as of Q2 2026.
- BNP Paribas Financial Markets bought 99,228 Perspective Therapeutics shares in Q2 2026, an estimated $375K.
- Perspective Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3863 holding.
- BNP Paribas Financial Markets first reported a position in Perspective Therapeutics in Q4 2013 and has held it in 17 quarters since.
- BNP Paribas Financial Markets's Perspective Therapeutics position peaked at $835K in Q2 2025.
- 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.